Plus Therapeutics raises ~$3.7M in secured convertible notes, exchanges warrants, and receives $2M CPRIT advance

PLUS THERAPEUTICS, INC.

Issued $3.36M in secured convertible notes and warrants to purchase ~3M shares at $1.12; aggregate proceeds ~$3.7M.
Exchanged $3.19M of existing Series A warrants for new secured convertible exchange notes.
Notes mature Feb 2026, 10% interest, secured by substantially all assets; mandatory conversion if $10M+ qualified financing by March 31, 2025.
Received $2.0M advance from CPRIT as part of existing $17.6M grant.
Registration rights with liquidated damages of 1%/month (12% cap) for filing/effectiveness delays.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-028151
form_type: 8-K
ticker: PSTV
cik: 0001095981
company_name: PLUS THERAPEUTICS, INC.
filed_at: 2025-02-18T23:59:59+00:00
discovered_at: 2026-05-14T18:03:02.918947+00:00
generated_at: 2026-05-26T13:53:21.346702+00:00
sec_items: ["1.01", "2.03", "3.02", "7.01", "9.01"]
event_type: debt
sentiment: neutral
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-028151
json_url: https://secwatch.observer/filing/0001193125-25-028151.json
markdown_url: https://secwatch.observer/filing/0001193125-25-028151.md
text_url: https://secwatch.observer/filing/0001193125-25-028151.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312525028151/0001193125-25-028151-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312525028151/d916701d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-028151

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.